Seribantumab
From Wikipedia the free encyclopedia
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Source | Human |
| Target | HER3 |
| Clinical data | |
| Other names | MM-121 |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| IUPHAR/BPS | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6340H9810N1690O1986S52 |
| Molar mass | 143151.18 g·mol−1 |
Seribantumab (INN;[1] development code MM-121) is a monoclonal antibody designed for the treatment of cancer.[2] It binds to extracellular domain of HER3 blocking NRG1 binding and thereby preventing the activation of the receptor.[3]
This drug was developed by Sanofi/Merrimack Pharmaceuticals, Inc.
References[edit]
- ^ World Health Organization (2012). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 108" (PDF). WHO Drug Information. 26 (4).
- ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Seribantumab, American Medical Association.
- ^ Rendell A, Thomas-Bland I, McCuish L, Taylor C, Binju M, Yu Y (August 2022). "Targeting Tyrosine Kinases in Ovarian Cancer: Small Molecule Inhibitor and Monoclonal Antibody, Where Are We Now?". Biomedicines. 10 (9): 2113. doi:10.3390/biomedicines10092113. PMC 9495728. PMID 36140214.
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |